TSHA Q4 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+44.0% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$16M-450.8% margin

Net Income

$48M1324.7% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

-24.1%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$173M

Total Liabilities

$98M

Stockholders' Equity

$75M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+44.0%
Gross Profit	$4M	$823,000	+337.9%
Operating Income	-$16M	-$19M	+13.1%
Net Income	$48M	-$56M	+185.7%